Virus Carrier State Suppresses Tumorigenicity of Tumor Cells in Athymic (Nude) Mice
(Accepted 2 October I978 ) SUMMARY Nude mice injected subcutaneously with normal uninfected BHK 21 cells or HeLa cells regularly develop large, rapidly-growing tumours at the subcutaneous site of inoculation. However, these same tumour cell lines when persistently infected with VSV or other enveloped RNA viruses are either rejected or form small nodules in nude mice. This rejection phenomenon probably involves some type of immunocyte since heavily-irradiated nude mice (500 rads) cannot reject persistently infected cells but develop large, rapidly-growing tumours which shed virus and defective interfering virus (DI) and which do not exhibit the lymphocytic infiltration observed in the nodules of unirradiated mice given persistently infected cells. Finally, it was possible to select a subline of BHK 2I-VSV carrier cells which regularly produces large rapidly-growing tumours in normal unirradiated nude mice, although all these carrier cells express virus antigen and shed large amounts of mature infectious virus and DI both in vivo and in vitro.
Due to its T-cell deficiency, the athymic nude mouse is unable to reject allogeneic and xenogeneic tissue transplants (Pantelouris, I968; Rygaard, 1973 ) and is, therefore, an excellent host for assay of tumorigenicity of most cell types (Klinger et al. 1976; Freedman & Shin, I974; Stiles et al. 1976 ). However, despite this deficiency ofT-cell rejection mechanisms, the nude mouse is not totally immunologically incompetent (Koene et al. I974) . In fact, the mice usually exhibit approximately normal levels of spontaneous tumour formation (Rygaard, I973) , an enhanced activated macrophage response to intracellular bacterial infections and certain strong but, as yet, ill-defined, cellular responses to foreign cells and infectious agents (Maguire et al. 1976; Haller et al. 1977; Miller et al. 1977; Lefkowits, 1978) .
It is known that both tumour virus-induced and chemically-induced tumour cells may express strong tumour-specific transplantation antigens at the cell surface, but these do not normally prevent tumorigenesis by the tumour cells in the athymic nude mouse (Rygaard, I973; Klinger et al. I976; Freedman & Shin, I974; Stiles et al. I976; Reid & Shin, I978) . However, we demonstrate here that persistent, non-cytopathic infection of tumour cells by a number of enveloped RNA viruses suppresses tumorigenicity of the tumour cells to a remarkable degree in the nude mice. This suppression of tumorigenicity is apparently due to a strong cellular and/or humoral response by the nude mice against virus-encoded cell surface antigens or virus-altered tumour cell antigens, or other induced neoantigens since cells cured of persistent virus infection are again strongly tumorigenic and because whole body irradiation of the nude mouse abrogates the suppression of tumorigenesis of the virus infected cells.
It has been shown elsewhere (Holland & Villarreal, 1974) "~ VSV = vesicular stomatitis virus. :~ When a dosage curve was done, no dosage up to I "5 × Io 7 cells produced a rapidly-growing tumour, and a minimum of IO 4 cells was necessary to produce a visible nodule.
§ NWS FLU = influenza virus A (NWS strain).
persistently infected cells grow in vitro at normal or near normal rates even though nearly every cell is infected and expressing viral antigen at the plasma membrane as measured by fluorescent antibody and by quantitative 131I-labelled immunoglobulin binding assays (Holland et al. 1976; Villarreal & Holland, I976) . Apparently the continuous presence of DI and the accumulation of mutations in the virus allow the establishment of this permanent non-cytocidal carrier state by normally virulent RNA viruses. Surprisingly we found that these carrier cells do not express any tumorigenic potential when inoculated subcutaneously into nu/nu homozygous mice even though they grew rapidly in cell culture. BHK 21 cells always give rise to large and highly-vascularized tumours within three weeks of the injection, whereas the same cells persistently infected with VSV failed to produce any tumours within six weeks and longer, regardless of the number of cells injected. The persistently infected cells either formed a small benign nodule or there was no detectable growth at all of the injected cells. This is summarized in Table I which shows that this phenomenon was obtained with BHK 2I cells persistently infected with either VSV or influenza virus or mumps virus, or by HeLa cells persistently infected with either VSV or measles virus. In all cases the uninfected tumour cells formed rapidly-growing tumours in the nude mice and the corresponding virus carrier cells were either rejected (no nodule or tumour growth) or they formed a very slowly-growing or non-growing benign nodule.
These benign nodules are typically small, hard and poorly vascularized; histologically they show a fibrous reaction and encapsulation. The nodules persist in mice for six months or more, and the BHK 2I-VSV carrier cells within them remain viable indefinitely, since the nodules can be excised, minced and dispersed and their component cells immediately re-cultured as rapidly growing in vitro cell cultures. In every case these nodule cells were still BHK 2I-VSV carrier cells as evidenced by their hamster karyotype and by the fact that they continue to shed infectious virus and DI particles, and are resistant to challenge by VSV.
We have shown earlier that BHK 2 I-VSV carrier cells can be 'cured' of persistent VSV infection by cloning in the presence of antiviral antibody (Holland et al. I976 infection can be detected. We cannot rule out the presence of non-expressed virus genes, however.
It should be noted that BHK 2I cells 'cured' in vitro after more than 3 years of persistent VSV infection are once again highly tumorigenic in nude mice. Furthermore, mice immunized 2 weeks previously by infection with live virus can still support the growth of turnouts from injections of HeLa cells or BHK 2I cells. Finally, when mice carrying a benign nodule of BHK 2I-VSV carrier cells were injected weeks later on the contralateral side with from IO a to Io 7 normal BHK 2I cells they always developed a rapidly-growing, soft turnout. This suggests that the anti-tumour response to BHK 21-VSV carrier cells is directed at virus antigens or virus-altered tumour cell antigens or other virus-induced target molecules. This interpretation is corroborated by results from experiments in which Io 6 BHK 2I cells were co-injected with Io 6 BHK 2I-VSV carrier cells. The mixture of the two cell lines in the same inoculum produced tumours associated with, or surrounding benign nodules. Thus, even when localized to the same site, the host responds differently to the carrier cell line and its uninfected parental cell line (virus release from the carrier cells is too low (Holland et al. I976) to infect all associated normal BHK 2I cells).
The above results indicate that some form of cellular or humoral 'immune response' is controlling growth of tumour cells persistently infected by viruses. Since such a response by the nude mouse might be expected to be radiation-sensitive, as are most immunological responses, we examined the effect of high dosage whole body irradiation on the phenomenon. Radiation sensitivity of the response could rule out a trivial explanation for the difference in tumorigenicity of the parental and carrier cell lines: that the persistent virus infections of the tumour cells somehow damages their ability to grow in vivo although they grow at near normal rates in vitro.
Nude mice that were whole body irradiated with 5oo rads of caesium la5 and subsequently injected with BHK-VSV carrier cells all developed rapidly growing, soft, well-vascularized tumours. Tumours removed from irradiated mice and passaged in culture shed infectious virus and were resistant to challenge by homologous virus infection. Furthermore, infectious virus could be isolated from the spleens of these mice.
When mice were injected 12 days after irradiation, the VSV carrier cells produced tumours within three weeks after injection, but in mice injected with the carrier cells on the day of irradiation, the tumours appeared later (within 6 to 7 weeks after injection). Thus, there is an immune mechanism continuing to function for up to two or three weeks after irradiation. The virus carrier cells survive this residual immune response and then express their tumorigenic potential when the immune cells turn over and fail to be replaced after host irradiation.
Little is known about radiation effects on nude mouse immunocytes, although some are rather radiation-resistant (Bonmassar, 1978) . Presumably, our results are due to immunocyte depletion, but this large dosage of 5oo rads could have altered control of infected cells in other ways (by reduced interferon production, etc).
Histological sections of control uninfected BHK 21 or HeLa cell tumours showed less host response than that seen with BHK 2 I-VSV intected cells. Histological sections of the benign nodules formed by BHK 2I persistently infected with VSV showed a strong fibrous reaction and encapsulation, with extensive lymphocytic infiltration into the tumour mass. There is no fibrous reaction or infiltration and only a slight encapsulation at the boundary of the tumour cell growth either with tumours from uninfected cells in normal nude mice, or with the virus-infected carrier cells in the irradiated nude mice. Clearly, there is a cellular reaction to persistently-infected cells which can limit tumour growth in normal mice and which does not occur in heavily irradiated nude mice. :~ VSV surface glycoprotein antigen on the surface of cultured CAR4 or CAR4-P cells was determined on living unfixed cells grown in culture on glass slides (indirect fluorescent antibody test).
§ Mature infectious virus production ranged from Io -2 to Io -5 p.f.u./cell for CAR4 and from i01 to I03/cell for CAR4-P (as determined on I0 % minced tumour suspensions & vivo, or on cell culture fluids in vitro). Mature DI production was determined by one stage amplification assays (Holland et al. I976) on I0 % suspensions of minced tumour suspensions.
After periods of several months or more (4 to 6), a small percentage of the nude mice carrying small nodules of persistently-infected cells eventually did develop soft, rapidlygrowing tumours. Almost all of these, upon excision, proved to be BHK 2I cells which had become 'cured' of virus infection. However, a few of these late-arising tumours did shed virus, and when passaged in cell culture were shown to be carrier cultures shedding infectious virus and exhibiting strong immunity to homologous VSV challenge infection.
We excised one such virus-shedding tumour which arose from a nodule of BHK 2I-VSV carrier cells after it had maintained benign nodular characteristics for 7 months. The persistently-infected BHK 21 cells from this tumour rapidly re-established growth in vitro and they shed both infectious virus and DI particles continuously in cell culture. Upon re-injection into another nude mouse they formed a large soft tumour similar to uninfected BHK 21 cells but which was highly invasive. Once again, excision of this second passage tumour after several months provided cultured cells which shed virus and DI and which were resistant to VSV challenge. This selected 'virus-positive' tumour has repeatedly been serially passaged in nude mice, and it continues to produce large amounts of virus and DI in vivo (Table 2 ). Virus and DI have been isolated regularly from the blood, spleens, kidneys and livers of these mice. This tumour provides an excellent model for cellular and biochemical studies of virus persistence in vivo. Surprisingly, this virus-positive tumour sheds much higher levels of virus and mature DI in vivo and in vitro than standard carrier cells, and it expresses higher levels of virus antigen both intracellularly and at the cell surface ( Table 2) . The mechanism by which it is able to escape the above reported tumour suppressive ability of nude mice for virus infected cells is under investigation. The nature of tumour antigens is poorly understood even in isologous host systems, and there is probably considerable heterogeneity in the host anti-tumour response (Reid & Shin, I978) .
The nature of the 'anti-tumour' response mounted by the nude mice against virusinfected tumour cells is being explored and is probably cellular, since it is radiations sensitive. This response might be important in well-known difficulties of heterografting certain types of human tumours such as prostatic carcinoma into the nude mice (Reid & Shin, I978) . Moreover, studies trying to correlate in vitro cellular phenotypes with malignancy where malignant transformation of a cell line is assayed by its tumorigenicity in nude mice (Klinger et al. 1976; Stiles et al. I976 ) , should be re-evaluated since some cell lines found to be non-tumorigenic may, in fact, be malignant but immunologically suppressed by the nude mice.
Finally, the ability to maintain persistently infected cells in nodules in vivo for periods exceeding six months (and in certain selected cells as tumours, indefinitely) followed by rapid re-establishment in cell culture should allow better analysis of cellular and biochemical parameters of persistent virus infection. Recent in vitro studies (Minato et al. 1979) indicate strongly that natural killer (NK) cells (and not B or T cells) are the immunocytes responsible for the nude mouse rejection of persistently-infected cells reported above. An auxiliary role of humoral antibody cannot be ruled out since we find low levels of virus-neutralizing antibody in most nude mice with VSV carrier cell nodules or tumours.
Note added inproof After this work was completed we discovered that a similar rejection of tumour cells persistently infected by Sendai virus was shown by Yamada & Hatano (1972) in normal hamsters.
